解开圆形RNA在炎症性肺部疾病中的作用
Asif Ahmad Bhat1, Gaurav Gupta2, Ahsas Goyal3
1School of Pharmacy, Suresh Gyan Vihar University, Jagatpura 302017, Mahal Road, Jaipur, India.
Naunyn-Schmiedeberg's archives of pharmacology
|November 2, 2023
概括
循环RNAs (circRNAs) 调节了喘和COPD等肺部疾病中的基因表达和炎症. 了解这些circRNAs为炎症性肺部疾病提供了新的治疗和诊断策略.
科学领域:
- 分子生物学分子生物学
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 循环RNAs (circRNAs) 是基因表达的关键调节者.
- 炎症性肺部疾病,包括喘,COPD和COVID-19,涉及不调节的炎症反应.
- 在肺部疾病中,circRNAs显示出调节炎症相关途径的潜力.
研究的目的:
- 审查目前对炎症性肺部疾病中circRNAs的理解.
- 专注于circRNAs的调节机制和功能影响.
- 突出circRNAs作为潜在的治疗点和诊断生物标志物.
主要方法:
- 关于circRNAs和炎症性肺部疾病研究的文献综述.
- 对circRNA调节机制 (miRNA海绵,蛋白相互作用,ceRNA网络) 的分析.
- 在各种肺部疾病中检查circRNA表达模式.
主要成果:
- 循环RNAs通过泡miRNAs,结合蛋白质和参与ceRNA网络来调节炎症.
- 在炎症性肺病中,特定的circRNAs被差异表达.
- circRNAs影响免疫细胞激活,细胞因子的产生和组织重塑.
结论:
- circRNAs在炎症性肺部疾病的发病过程中起着重要的作用.
- circRNAs代表了新型治疗干预措施的有希望的目标.
- 对circRNA功能的进一步研究可以推进疾病管理策略.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Drugs Used in Lower Respiratory Disorders: Overview
455
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
455


